Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

BACKGROUND: We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is still unclear. METHODS: The neoadjuvant GeparQuinto tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Witzel, I, Loibl, S, von Minckwitz, G, Eidtmann, H, Fehm, T, Khandan, F, Schmatloch, S, Hauschild, M, Bischoff, J, Fasching, P A, Mau, C, Schem, C, Rack, B, Meinhold-Heerlein, I, Liedtke, C, Karn, T, Huober, J, zu Eulenburg, C, Issa-Nummer, Y, Untch, M, Müller, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464767/
https://www.ncbi.nlm.nih.gov/pubmed/22892393
http://dx.doi.org/10.1038/bjc.2012.353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464767/
https://www.ncbi.nlm.nih.gov/pubmed/22892393
http://dx.doi.org/10.1038/bjc.2012.353

Ejemplares similares